[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100644778":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":25,"centralContacts":31,"locations":37,"responsibleParty":58,"collaborators":25,"id":60,"slug":61,"hasResults":62,"nctId":63,"briefTitle":64,"officialTitle":65,"acronym":66,"eligibilityCriteria":67,"healthyVolunteers":62,"sex":68,"minAge":69,"maxAge":70,"enrollmentInfo":71,"targetDuration":25,"studyType":74,"phases":75,"briefSummary":77,"conditions":78,"keywords":25,"overallStatus":39,"whyStopped":25,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":89},{"fullName":5,"class":6},"Buckinghamshire Healthcare NHS Trust","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"World Sight Foundation Field Machine","EXPERIMENTAL","Test Device",[13],"Device: World Sight Foundation Field Machine",{"label":15,"type":16,"description":17,"interventionNames":18},"Humphrey Visual Field Analyser","ACTIVE_COMPARATOR","gold standard of care comparator",[19],"Other: Comparator",[21,26],{"type":22,"name":9,"description":23,"armGroupLabels":24,"otherNames":25},"DEVICE","Test Intervention",[9],null,{"type":6,"name":27,"description":28,"armGroupLabels":29,"otherNames":30},"Comparator","Gold Standard of Care (Comparator)",[15],[15],[32],{"name":33,"role":34,"phone":35,"phoneExt":25,"email":36},"James Cooper","CONTACT","07816020305","james.cooper9@nhs.net",[38],{"facility":5,"status":39,"city":40,"state":25,"zip":25,"country":41,"countryCode":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":49},"RECRUITING","Aylesbury","United Kingdom","UK",{"type":44,"coordinates":45},"Point",[46,47],-0.81458,51.81665,{"lat":47,"lon":46},[50,54,56],{"name":51,"role":34,"phone":52,"phoneExt":25,"email":53},"Matthew Kinsella, MD","+441296 831378","bht.research@nhs.net",{"name":55,"role":34,"phone":52,"phoneExt":25,"email":36},"James Cooper, BSc, MSc",{"name":51,"role":57,"phone":25,"phoneExt":25,"email":25},"PRINCIPAL_INVESTIGATOR",{"type":59,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR","100644778","world-sight-foundation-field-machine-wsffm-pilot-100644778",false,"NCT07674069","World Sight Foundation Field Machine (WSFFM) Pilot","Clinical Testing Pilot of the World Sight Foundation Field Machine (WSFFM) in Glaucoma Patients - Comparison With Humphrey Visual Field Analyser","WSFFM","Inclusion Criteria:\n\n* \\- Patients attending glaucoma outpatient clinic\n* Patients requiring visual field testing, with plan for \"SITA-STANDARD\" HVF testing\n* Patients 18 years or older and of any gender\n* Patients capable of giving informed consent.\n\nExclusion Criteria:\n\n* \\- Patients not requiring visual field testing on that outpatient clinic attendance.\n* Patients requiring visual field testing, with plan for \"SITA-FAST\" or \"SITA-FASTER\" HVF testing.\n* Patients who do not attend their outpatient clinic appointment,\n* Patients not able to perform visual field testing (for example due to their visual acuity, physical difficulty in positioning for test duration, or cognitive difficulties in understanding instructions).\n* Patients under the age of 18 years old.","ALL","18 Years","99 Years",{"count":72,"type":73},100,"ESTIMATED","INTERVENTIONAL",[76],"NA","The current situation outside of large cities in lower-income countries, as described above, is suboptimal for the diagnosis of glaucoma. Doctors have no means of assessing visual fields, and as such may not be able to identify the condition until too advanced for any meaningful intervention (ie, to enable preservation of vision). Vision loss from glaucoma is irreversible. Understanding, through this pilot study, how well the World Sight Foundation Field Machine (WSFFM) works is an essential step towards trialling its use in lower-income countries. The justification for enabling this is to allow clinicians in the developing world to make more informed assessments of their glaucoma patient's status; this should translate in more timely treatments or referral for further investigation before further irreversible vision loss.\n\nThe WSFFM will be compared to the Humphrey Visual Field (HVF) analyser. The HVF analyser is the gold standard method of measuring visual fields; in our hospital eye service it is almost exclusively the method used, and as such the field technicians are particularly skilled in their use. The output data of the HVF enables easy quantification of level of field loss; by comparing the output from the WSFFM it would be possible to allow some form of quantification against \"the standard\" such that an idea of how well it works may be calculated.",[79],"Glaucoma","2026-06-25",{"date":82,"type":83},"2026-06-29","ACTUAL",{"date":85,"type":83},"2026-04-29",{"date":87,"type":73},"2026-07-01",{"name":5,"class":6},1]